Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0)

Tania A. Smith, Carlos Hoyo-Vadillo, Akosua Agyeman Adom, Liliana Favari-Perozzi, Silke Gastine, Hakim Moulay Dehbi, Beatriz Villegas-Lara, Eduardo Mateos, Yessica Sara Pérez González, Maria D. Navarro-Gualito, Alejandra S. Cruz-Carbajal, Miguel A. Cortes-Vazquez, Carolina Bekker-Méndez, Charmina Aguirre-Alvarado, Gisela Aguirre-Gil, Lucero Delgado-Pastelin, Andrew Owen, David Lowe, Joseph Standing, Jorge Escobedo

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (Trials, (2022), 23, 1, (583), 10.1186/s13063-022-06533-0)'. Together they form a unique fingerprint.

Medicine & Life Sciences